New York, New York, United States Funds with similar focus
| Fund Name | Location |
| Density Ventures | Canada, Ontario, Toronto |
| Eir Partners | - |
| FINANCIERE FONDS PRIVES | France, Ile-de-France, Paris |
| Fucheng Touzi | China, Guangdong Province, Guangzhou City |
| Hemeria | France, Ile-de-France, Paris |
| Hongshi Capital Management | Beijing, Beijing, China |
| Horizons Labs | - |
| Inglewood Ventures | California, San Diego, United States |
| IONIQ | Berlin, Berlin, Germany |
| Koffler Group | - |
| Kubera Partners | Garden City, New York, United States |
| Redmile Group | California, San Francisco, United States |
| SAT Capital | - |
| Shenzhen Qianhai Wanrong Hongtu Investment Fund | China, Guangdong, Shenzhen |
| Western Union Accelerator Powered by Techstars | Colorado, Denver, United States |
| Wieland Capital | Bayern, Germany, München |
| Zhengu | Beijing, Beijing, China |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
PGxCare | $1M | 19 Mar 2024 | Palo Alto, California, United States | ||
Deka Biosciences | $20M | 28 Sep 2023 | Washington, District of Columbia, United States | ||
Triumvira Immunologics | $45M | 17 Mar 2022 | Austin, Texas, United States | ||
Iridia | $24M | 16 Mar 2021 | Carlsbad, California, United States |
– Amolyt Pharma from Lyon develops therapeutic peptides for rare endocrine and related diseases.
– The company closed an $80m Series B round.
– The round was co-led by Sectoral Asset Management and Andera Partners, with participation from ATEM Capital, LSP, Novo Holdings (Novo Ventures), Kurma Partners, Mass General Brigham Ventures, Innobio 2 managed by Bpifrance, Orbimed, Pontifax, Eurazeo, Sham Innovation Santé/Turenne Capital and Credit Agricole Creation.
– The company plans to use the proceeds from the financing to advance its pipeline of potential therapeutics for rare endocrine and related diseases, including clinical development of AZP-3601 for hypoparathyroidism, pre-clinical development of AZP-3813 for acromegaly and ongoing research related to AZP-3404, and to further expand its early-stage pipeline through both internal research and development activities and potential in-licensing opportunities.
– Amolyt Pharma from Lyon develops therapeutic peptides for rare endocrine and related diseases.
– The company closed an $80m Series B round.
– The round was co-led by Sectoral Asset Management and Andera Partners, with participation from ATEM Capital, LSP, Novo Holdings (Novo Ventures), Kurma Partners, Mass General Brigham Ventures, Innobio 2 managed by Bpifrance, Orbimed, Pontifax, Eurazeo, Sham Innovation Santé/Turenne Capital and Credit Agricole Creation.
– The company plans to use the proceeds from the financing to advance its pipeline of potential therapeutics for rare endocrine and related diseases, including clinical development of AZP-3601 for hypoparathyroidism, pre-clinical development of AZP-3813 for acromegaly and ongoing research related to AZP-3404, and to further expand its early-stage pipeline through both internal research and development activities and potential in-licensing opportunities.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
PGxCare | $1M | 19 Mar 2024 | Palo Alto, California, United States | ||
Deka Biosciences | $20M | 28 Sep 2023 | Washington, District of Columbia, United States | ||
Triumvira Immunologics | $45M | 17 Mar 2022 | Austin, Texas, United States | ||
Iridia | $24M | 16 Mar 2021 | Carlsbad, California, United States |
